Evidence map›Paper›PMID 41524401›Full record

ArticlemBio2026

A VLP-based mRNA vaccine elicits potent humoral and cellular immunity against Oropouche virus.

Yuren Shi, Guangxu Zhang, Siyu Lin, Mengyu Hu, Yuanzhou Wang, Haoyu Ge, Shuai Xia, Qian Wang, Shibo Jiang, Lu Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuren Shi *Key Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.ORCID 0009-0000-9555-5719
Guangxu Zhang *Key Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Siyu LinSchool of Basic Medicine, Dali University, Dali, China.
Mengyu HuKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yuanzhou WangKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Haoyu GeKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shuai XiaKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qian WangKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.ORCID 0000-0001-5322-0283
Shibo JiangKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.ORCID 0000-0001-8283-7135
Lu LuKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Science), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.ORCID 0000-0002-2255-0391

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oropouche virus (OROV) is reemerging in the Americas, along with a growing threat to global public health. Recent outbreaks have witnessed the first reported fatalities, vertical transmissions, and intercontinental importations of OROV, underscoring its expanding risk. Despite this, no vaccines or specific therapeutics are available, and fundamental research on OROV vaccinology and antigenicity remains limited. Here, we show that co-expression of the M polyprotein and nucleocapsid protein (NP) drives the assembly of OROV virus-like particles (VLPs) with high immunogenicity. Using the prototype strain OROV/sloth/Brazil/PA-UG-BeAn19991/1960, we developed an mRNA vaccine, M/N-vac, encoding these VLPs. Immunization with M/N-vac in mice elicited robust OROV-specific IgG and pseudovirus-neutralizing antibodies that cross-reacted with a contemporary circulating strain, hOROV/Brazil/AM-UKY-AM0088/2024. The vaccine also induced a durable, antigen-specific Th1-biased cellular immune response characterized by high-level interferon-gamma secretion. Additionally, we identified a highly conserved potential immunodominant epitope in BALB/c, N2-3, within the nucleocapsid protein. Furthermore, the VLP-encoding mRNA vaccine induced stronger OROV-specific humoral and cellular immune responses than the VLP protein vaccine.

Indexed as

Bunyaviridae InfectionsImmunity, CellularImmunity, HumoralOrthobunyavirusVaccines, Virus-Like ParticleViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleImmunoglobulin GMiceMice, Inbred BALB CmRNA VaccinesNucleocapsid ProteinsAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GmRNA VaccinesNucleocapsid ProteinsVaccines, Virus-Like ParticleViral Vaccinescross-reactive antibodiesmRNA vaccineOropouche virus (OROV)virus-like particles (VLPs)

Identifiers

PMID41524401
PMCPMC12892965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.